GALECTIN THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 31, 2025.
| GALECTIN THERAPEUTICS INC. | |
| By: | /S/ JOEL LEWIS |
| Name: JOEL LEWIS. | |
| Title: Chief Executive Officer and President |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /S/ JOEL LEWIS | Chief Executive Officer, President and Director | March 31, 2025 |
| Joel Lewis | (principal executive officer) | |
| /S/ JACK W. CALLICUTT | Chief Financial Officer | March 31, 2025 |
| Jack W. Callicutt | (principal financial and accounting officer) | |
| /S/ RICHARD E. UIHLEIN | Director and Chairman of the Board | March 31, 2025 |
| Richard E. Uihlein | ||
| /S/ GILBERT F. AMELIO, Ph.D. | Director | March 31, 2025 |
| Gilbert F. Amelio, Ph.D. | ||
| /S/ BENJAMIN S. CARSON, SR., M.D. | Director | March 31, 2025 |
| Benjamin S. Carson, Sr., M.D. | ||
| /S/ KARY ELDRED | Director | March 31, 2025 |
| Kary Eldred | ||
| /S/ KEVIN D. FREEMAN | Director | March 31, 2025 |
| Kevin D. Freeman | ||
| /S/ GILBERT S. OMENN, M.D., Ph.D. | Director | March 31, 2025 |
| Gilbert S. Omenn, M.D., Ph.D. | ||
| /S/ MARC RUBIN, M.D. | Director | March 31, 2025 |
| Marc Rubin, M.D. | ||
| /S/ ELISSA J. SCHWARTZ, Ph.D. | Director | March 31, 2025 |
| Elissa J. Schwartz, Ph.D. | ||
| /S/ HAROLD H. SHLEVIN, Ph.D. | Director | March 31, 2025 |
| Harold H. Shlevin, Ph.D. | ||
| /S/ RICHARD A. ZORDANI | Director | March 31, 2025 |
| Richard A. Zordani | ||
Index
Galectin Therapeutics Inc. and subsidiaries
Table of Contents
| 1. | Reports of Independent Registered Public Accounting Firm (PCAOB ID 677) | F-1 |
| 2. | Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| 3. | Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-4 |
| 4. | Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 | F-5 |
| 5. | Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-7 |
| 6. | Notes to Consolidated Financial Statements | F-8 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.